TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35897119

Group type: EXPERIMENTAL
Intervention: Safety planning and telephone follow-up intervention (SAFETEL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study: 33285143

Group type: EXPERIMENTAL
Intervention: mPOCT for influenza
Number of subjects: 613

Group type: COMPARATOR
Intervention: Routine clinical care (control group)
Number of subjects: 613
Study: 35831082

Group type: EXPERIMENTAL
Intervention: CLEAN Meds intervention (short list of essential medicines)
Number of subjects: 379
Study: 33300880

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment on the intervention side (axilla or groin)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control side (contralateral side)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment on the intervention side
Number of subjects: 17
Study: 35337672

Group type: EXPERIMENTAL
Intervention: Combined exercise and dietary intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care with counseling sessions post-treatment
Number of subjects: 24
Study: 33523004

Group type: EXPERIMENTAL
Intervention: Cycling (moderate-intensity, 20-50 minutes, 3 times a week for 6 months)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stretching (light-intensity)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 96
Study: 32878899

Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early administration of tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe TBI treatment with tranexamic acid
Number of subjects: 0
Study: 34628421

Group type: EXPERIMENTAL
Intervention: Visco-circumferential-suture-trabeculotomy (VCST)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Rigid probe viscotrabeculotomy (VT)
Number of subjects: 49
Study: 32895571

Group type: EXPERIMENTAL
Intervention: Avelumab + axitinib
Number of subjects: 886

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 886
Study: 35576873

Group type: EXPERIMENTAL
Intervention: Magnesium + Vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Magnesium + Vitamin D (MagD)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vitamin D only (VitD; 1000 IU vitamin D 3 × daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 32376505

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 484

Group type: COMPARATOR
Intervention: External validation models
Number of subjects: 484
Study: 35172779

Group type: EXPERIMENTAL
Intervention: ADT combined with modified docetaxel chemotherapy (docetaxel 40 mg/m2 on the 1st day and 35 mg/m2 on the 8th day, repeated every 21 days)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ADT combined with modified docetaxel chemotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: ADT combined with standard docetaxel chemotherapy
Number of subjects: 128
Study: 34173659

Group type: EXPERIMENTAL
Intervention: Platelia Aspergillus galactomannan (GM) enzyme immunoassay (EIA)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Fungitell β‐d‐glucan (BDG) assay
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Combination of GM EIA and BDG assay
Number of subjects: 471

Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 471

Group type: COMPARATOR
Intervention: Caspofungin prophylaxis
Number of subjects: 471
Study: 35013991

Group type: EXPERIMENTAL
Intervention: Response-contingent group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random group
Number of subjects: 0
Study: 35486948

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) in combination with transdermal estradiol (t‐E2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) in combination with transdermal estradiol (t‐E2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both MP and MPA
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 57
Study: 35040887

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (ticagrelor or clopidogrel) plus therapeutic dose of heparin (n=293)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Therapeutic dose of heparin only (usual care) (n=269)
Number of subjects: 562
Study: 33745624

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (less than vs. more than median value)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (less than vs. equal or more than RDA)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (median)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (equal or more than RDA)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (more than median)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary iron intake (equal or more than RDA)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 466
Study: 34344399

Group type: EXPERIMENTAL
Intervention: Sapropterin at 10 mg/kg/day (increased up to 20 mg/kg/day) plus Phe-restricted diet in the 'sapropterin extension' group (n = 26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sapropterin plus Phe-restricted diet in the 'sapropterin continuous' group (n = 25)
Number of subjects: 51
Study: 32157182

Group type: EXPERIMENTAL
Intervention: Corneal stromal pocket irrigation with balanced salt solution
Number of subjects: 121

Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 121
Study: 34910297

Group type: EXPERIMENTAL
Intervention: Thalidomide (THD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 34660195

Group type: EXPERIMENTAL
Intervention: Maxingshigan-Weijing Decoction (MWD) with routine supportive care
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine supportive care alone
Number of subjects: 59
Study: 33118624

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 68
Study: 32423937

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 34061234

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy/cervicopexy (LSC‐Cx)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anterior vaginal mesh (AVM)
Number of subjects: 120
Study: 33545954

Group type: EXPERIMENTAL
Intervention: Acoustic therapy combined with acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 0
Study: 36617611

Group type: EXPERIMENTAL
Intervention: Intranasal acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medicine (budesonide nasal spray and loratadine)
Number of subjects: 120
Study: 32919848

Group type: EXPERIMENTAL
Intervention: Topical Vancomycin Powder and Dilute Povidone-Iodine Lavage (VIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk TKA patients
Number of subjects: 0
Study: 33199418

Group type: EXPERIMENTAL
Intervention: Low-flow oxygen with head side elevation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: High-flow oxygen with head side elevation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care (no oxygen provided)
Number of subjects: 138
Study: 35732183

Group type: EXPERIMENTAL
Intervention: Intervention providing appointment and referral opportunity to community therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (Intervention + TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention and TAU
Number of subjects: 0
Study: 34506827

Group type: EXPERIMENTAL
Intervention: Genotype-guided treatment with ticagrelor for carriers of CYP2C19 loss-of-function alleles and clopidogrel for noncarriers.
Number of subjects: 755

Group type: COMPARATOR
Intervention: Standard treatment with clopidogrel.
Number of subjects: 755
Study: 36289532

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7+3
Number of subjects: 0
Study: 33449510

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion (HS)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Cognitive-behavioral pain psychoeducation
Number of subjects: 285
Study: 34081560

Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODT) 20 mg daily, adjusted weekly by 10-20 mg during a 4-week dose-optimization period.
Number of subjects: 0
Study: 32615117

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36109354

Group type: EXPERIMENTAL
Intervention: 1% Methylene Blue (MB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% Methylene Blue (MB) and 0.75% Ropivacaine mixture
Number of subjects: 90
Study: 34795121

Group type: EXPERIMENTAL
Intervention: epidermal growth factor receptor‐tyrosine kinase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cytotoxic chemotherapeutic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: immune checkpoint inhibitors
Number of subjects: 0
Study: 35499834

Group type: EXPERIMENTAL
Intervention: Structured, 2-year, partially supervised, moderate-intensity physical activity and exercise intervention
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Health education control intervention
Number of subjects: 1199
Study: 32316864

Group type: EXPERIMENTAL
Intervention: Amazake
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 36180923

Group type: EXPERIMENTAL
Intervention: BEAM app-based program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33725939

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microsurgical clipping
Number of subjects: 0
Study: 34075841

Group type: EXPERIMENTAL
Intervention: Oral administration of Ellagic Acid (100 mg) plus Annona Muricata (100 mg), daily for 6 months
Number of subjects: 162
Study: 32771313

Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm using U-Net architecture for SAT and VAT quantification
Number of subjects: 7

Group type: COMPARATOR
Intervention: Manual segmentation of SAT and VAT
Number of subjects: 7

Group type: COMPARATOR
Intervention: Automated segmentation of SAT and VAT
Number of subjects: 7
Study: 33506965

Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acid (n‐3 LCPUFA) supplementation during third trimester of pregnancy
Number of subjects: 736
Study: 32612066

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 83
Study: 35301859

Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34362409

Group type: EXPERIMENTAL
Intervention: Community-based stepwise diabetes prevention program with added financial incentives
Number of subjects: 846
Study: 32475446

Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 400 mg/kg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 200 mg/kg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Star anise oil (SAO) supplementation at 600 mg/kg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Star anise oil (SAO) supplementation at 0 mg/kg (control)
Number of subjects: 512

Group type: COMPARATOR
Intervention: E. coli challenge
Number of subjects: 512
Study: 35421071

Group type: EXPERIMENTAL
Intervention: EndoTrac ESD
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 150
Study: 33372291

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACSs) - betamethasone or dexamethasone
Number of subjects: 982
Study: 32819997

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention prior to vaccination in addition to standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 100
Study: 35944021

Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity (1, 0.76, 0.54, and 0.31 gravity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Walking speed (0.4, 0.8, 1.2, and 1.6 m/s)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow walking (0.4 m/s)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intrinsic muscle-tendon unit stiffness
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 12
Study: 33065258

Group type: EXPERIMENTAL
Intervention: vNOTES hysterectomy
Number of subjects: 114
Study: 36862239

Group type: EXPERIMENTAL
Intervention: 12 mg dexamethasone daily
Number of subjects: 357

Group type: COMPARATOR
Intervention: 6 mg dexamethasone daily
Number of subjects: 357
Study: 33148620

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 3200 mg/m2)
Number of subjects: 349

Group type: COMPARATOR
Intervention: FOLFOX plus bevacizumab (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 then 2400 mg/m2)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 349

Group type: COMPARATOR
Intervention: FOLFOX plus bevacizumab
Number of subjects: 349
Study: 36164744

Group type: EXPERIMENTAL
Intervention: Online clinical mentoring sessions (6 sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Asynchronous online lectures (6 lectures)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Online clinical mentoring
Number of subjects: 24
Study: 33882970

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with sufentanil and dezocine‐based PCIA (group D)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Sufentanil and dezocine‐based PCIA (group C)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study: 33313730

Group type: EXPERIMENTAL
Intervention: Mobile+Group LAMP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile LAMP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 34368934

Group type: EXPERIMENTAL
Intervention: Friendly Schools Friendly Families (FSFF) anti-bullying intervention
Number of subjects: 0
Study: 33308359

Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid daily)
Number of subjects: 8208

Group type: COMPARATOR
Intervention: Enalapril only (10 mg daily)
Number of subjects: 8208
Study: 35918106

Group type: EXPERIMENTAL
Intervention: Daprodustat three times weekly
Number of subjects: 407

Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 407
Study: 33251687

Group type: EXPERIMENTAL
Intervention: Deep injection technique targeting the supraperiosteal plane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Superficial injection technique in the superficial fatty layer
Number of subjects: 14
Study: 33371123

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with conventional treatment (treatment A) for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment alone (treatment C) for 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with conventional treatment (treatment A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment alone (treatment C)
Number of subjects: 40
Study: 34480570

Group type: EXPERIMENTAL
Intervention: 60 days of complete bed rest with energy intake reduced to maintain energy balance and fat mass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standardized culture conditions for adipose tissue
Number of subjects: 20
Study: 32870801

Group type: EXPERIMENTAL
Intervention: Hybrid learning method for system identification and optimal control using neural networks and reinforcement learning.
Number of subjects: 0
Study: 33337706

Group type: EXPERIMENTAL
Intervention: G40% (40% of body mass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: G0% (0% of body mass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: G60% (60% of body mass)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: G80% (80% of body mass)
Number of subjects: 60
Study: 35181234

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no self-hypnosis)
Number of subjects: 78
Study: 32424335

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 25
Study: 35365841

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and/or azithromycin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (nonenrolled patients)
Number of subjects: 53
Study: 33812221

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis (MS)
Number of subjects: 27209
Study: 34676916

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (IL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3-month post-placement loaded implants (DL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Platform switched implants
Number of subjects: 32

Group type: COMPARATOR
Intervention: Platform matching implants
Number of subjects: 32
Study: 33257485

Group type: EXPERIMENTAL
Intervention: Fluoxetine for 6 months
Number of subjects: 3127

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 3127
Study: 33310202

Group type: EXPERIMENTAL
Intervention: Integrative Educational Intervention of Altruism (IEIA) for 14 weeks
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study: 32519507

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for 10 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 78
Study: 35142082

Group type: EXPERIMENTAL
Intervention: Combined training (CT); 6 months, 3 sessions per week, including resistance training and aerobic exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined training (CT); 6 months
Number of subjects: 40
Study: 33017510

Group type: COMPARATOR
Intervention: Olaparib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib in combination with bevacizumab
Number of subjects: 0
Study: 35437789

Group type: EXPERIMENTAL
Intervention: Culturally Informed and Flexible Family Treatment for Adolescents (CIFFTA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Individually Oriented Treatment‐As‐Usual (ITAU)
Number of subjects: 200
Study: 34044690

Group type: EXPERIMENTAL
Intervention: AutonoMe with Clareon IOL
Number of subjects: 58

Group type: COMPARATOR
Intervention: iSert with Vivinex IOL
Number of subjects: 58
Study: 35674265

Group type: EXPERIMENTAL
Intervention: Modified Lim‐Tsai repair technique
Number of subjects: 10

Group type: COMPARATOR
Intervention: Asymmetric repair technique
Number of subjects: 10
Study: 33022293

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (n=69, 62%)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: BCG vaccine (n=12, 11%)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Numerous antivirals and immune enhancers
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis
Number of subjects: 112
Study: 32252820

Group type: EXPERIMENTAL
Intervention: VWLR2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SupLR, C, VWLR2, J, LRE, WC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LRL, VWLR, VWLR2, WC, J
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LR, LRE, VWLR, C, VWLR2, SupLR
Number of subjects: 0

Group type: COMPARATOR
Intervention: All tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weighted logrank tests
Number of subjects: 0
Study: 35690797

Group type: EXPERIMENTAL
Intervention: NEuRoMS intervention plus usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60
Study: 34726270

Group type: EXPERIMENTAL
Intervention: IGAxBSA
Number of subjects: 6518

Group type: COMPARATOR
Intervention: EASI
Number of subjects: 6518

Group type: COMPARATOR
Intervention: SCORAD
Number of subjects: 6518
Study: 33796955

Group type: EXPERIMENTAL
Intervention: Caffeine gel with 1% choline geranate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine gel without ionic liquid
Number of subjects: 0
Study: 35863837

Group type: EXPERIMENTAL
Intervention: Nomogram based on 12 characteristics (education, professional title, age, burnout, effort-reward imbalance, asbestos dust, hypertension, diabetes, working hours per day, working years, marital status, work schedule)
Number of subjects: 7118
Study: 33615506

Group type: EXPERIMENTAL
Intervention: In-center brochure and follow-up email
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Email only
Number of subjects: 847

Group type: COMPARATOR
Intervention: Control
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: In-center brochure plus email
Number of subjects: 847
Study: 32339943

Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lumbopelvic relaxing technique
Number of subjects: 32
Study: 36124526

Group type: EXPERIMENTAL
Intervention: 12 sessions of speech in noise training with a hearing aid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 33890579

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detection of myopic macular degeneration
Number of subjects: 226686

Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detection of high myopia
Number of subjects: 226686

Group type: COMPARATOR
Intervention: Deep learning algorithms compared to six human experts
Number of subjects: 226686

Group type: EXPERIMENTAL
Intervention: Blockchain technology for data transfer and model testing
Number of subjects: 226686